

# LexaGene Holdings Inc.

12:25 27 Jan 2020

## LexaGene bombarded with inquiries about pathogen detection platform for Coronavirus identification use

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF), the biotechnology company, is receiving numerous inquiries about its technology for detecting the deadly coronavirus, which first struck in the Chinese city of Wuhan.

The new pathogen, which can be identified with LexaGene's technology, surfaced last December when workers in Wuhan developed symptoms of severe pneumonia after being infected with this previously unknown virus.

READ: LexaGene is enabling faster, easier pathogen detection  
Dr. Jack Regan, LexaGene's CEO and founder, says the company's genetic analyzer can detect new pathogens such as the coronavirus in "just one hour, on-site".

"Currently the traditional process requires that samples from sick individuals must be transported to laboratories for manual processing," Regan said. "This is extremely inefficient and introduces a significant time-delay that can have severe consequences for disease spread. Today's coronavirus outbreak highlights why LexaGene's technology is needed so desperately."

At the start of this month, China's health officials formally identified that the infections in Wuhan stemmed from the coronavirus, which is also referred to as 2019-nCoV.

In response to the outbreak of the virus, China has quarantined entire cities and airports are now screening travelers who arrive via plane from areas that have been affected by the virus.

According to statistics provided by the World Health Organization, as of January 26, more than 2,000 cases have been confirmed and 56 deaths reported. The disease has spread to ten other countries, including the US, France, Canada and Australia.

Dr. Regan points out that LexaGene's technology can be used for detection purposes in clinics, hospitals and airports in one hour or less.

"Currently, no technology exists that allows for these locations to readily start screening for a new threat within days of an outbreak being identified," Regan continued. "LexaGene is addressing this urgent problem and has developed the first ever, easy-to-use, open-access diagnostic analyzer that is designed to help control the spread of deadly outbreaks such as this 2019 coronavirus."


LexaGene's pathogen detection platform is designed to detect both common pathogens as well as bio-threats. It is now putting the last touches on a commercial instrument, which is set to be manufactured in a few months and sold starting in the third quarter of this year.

The Massachusetts company will require either 510(k) clearance from the Food and Drug Administration or Emergency

**Price:** 0.82

**Market Cap:** \$93.24 m

### 1 Year Share Price Graph



September 2019 March 2020 September 2020

### Share Information

**Code:** LXG

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	1.28	0.43

**Sector:** Medical technology & services

**Website:** [www.lexagene.com](http://www.lexagene.com)

### Company Synopsis:

*LexaGene is a biotechnology company developing a fully automated pathogen detection platform for use at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Use Authorization to introduce its technology as a way to process human samples in hospitals, clinics and airports.

Shares advanced 5.71% in Toronto to stand at C\$0.74.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).